These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 28113129

  • 1. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L, Hobson S, Lees P.
    Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129
    [Abstract] [Full Text] [Related]

  • 2. Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
    Dorey L, Lees P.
    BMC Vet Res; 2017 Jun 23; 13(1):192. PubMed ID: 28645327
    [Abstract] [Full Text] [Related]

  • 3. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media.
    Dorey L, Hobson S, Lees P.
    Res Vet Sci; 2017 Apr 23; 111():43-48. PubMed ID: 27940285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?
    Dorey L, Hobson S, Lees P.
    J Vet Pharmacol Ther; 2017 Oct 23; 40(5):517-529. PubMed ID: 28101885
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacodynamics of marbofloxacin for calf pneumonia pathogens.
    Illambas J, Potter T, Cheng Z, Rycroft A, Fishwick J, Lees P.
    Res Vet Sci; 2013 Jun 23; 94(3):675-81. PubMed ID: 23375665
    [Abstract] [Full Text] [Related]

  • 9. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
    Blackall PJ, Asakawa T, Graydon RJ, White M, Adamson M, Wade LK, Lowe LB.
    Aust Vet J; 1995 Jan 23; 72(1):35-6. PubMed ID: 8787526
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of doxycycline and oxytetracycline against porcine respiratory pathogens.
    Bousquet E, Morvan H, Aitken I, Morgan JH.
    Vet Rec; 1997 Jul 12; 141(2):37-40. PubMed ID: 9253829
    [Abstract] [Full Text] [Related]

  • 15. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
    Shryock TR, Staples JM, DeRosa DC.
    J Vet Diagn Invest; 2002 Sep 12; 14(5):389-95. PubMed ID: 12296390
    [Abstract] [Full Text] [Related]

  • 16. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
    Moore GM, Basson RP, Tonkinson LV.
    Am J Vet Res; 1996 Feb 12; 57(2):224-8. PubMed ID: 8633813
    [Abstract] [Full Text] [Related]

  • 17. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
    Blondeau JM, Fitch SD.
    PLoS One; 2019 Feb 12; 14(1):e0210154. PubMed ID: 30629633
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.